EUVIMEDEUVIMED entdecken
Vergleichsstudie

Cost-effectiveness of cabotegravir versus tenofovir alafenamide plus emtricitabine versus tenofovir disoproxil fumarate plus emtricitabine for pre-exposure prophylaxis to prevent HIV-1 transmission in gay, bisexual and other men that have sex with men

Philip Erick Wikman-Jorgensen, Marta Ruiz-Algueró, Carlos Iniesta, Federico Pulido, Jara Llenas-García

Enfermedades infecciosas y microbiologia clinica (English ed.) · 2025

DOI: 10.1016/j.eimce.2024.12.014 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Enfermedades infecciosas y microbiologia clinica (English ed.), 2025. Verfasst von Philip Erick Wikman-Jorgensen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine & Infectious Diseases Department, Elda General University Hospital-FISABIO, Elda, Spain; Clinical Medicine Department, Universidad …. Hauptthemen laut MEDLINE: HIV Infections, Emtricitabine, Tenofovir, Pre-Exposure Prophylaxis. Die Arbeit nennt 46 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: This study aims to compare the cost-effectiveness of currently approved daily PrEP in Spain, with tenofovir disoproxil fumarate plus emtricitabine (TDF/FTC), in gay, bisexual and other men who have sex with men (GBMSM) versus newer alternatives like daily tenofovir alafenamide plus emtricitabine (TAF/FTC) or injectable cabotegravir every 2 months (CAB). METHODS: We fitted a dynamic compartmentalized Markov model that represents the dynamics of HIV-1 transmission in GBMSM in Spain. The model was calibrated to replicate the epidemiological data of the HIV epidemic in GBMSM in Spain from 2013 to 2018. We used the perspective of the national health system and applied a 40-year time horizon. Quality-adjusted life years (QALYs) were the health outcome variable, and the cost was accounted for in 2018 Euros (€). Our outcome variable was the incremental cost-effectiveness ratio (ICER) for PrEP. We used the 2018 gross domestic product per capita of Spain (€25,854) as the willingness-to-pay (WTP) threshold. RESULTS: The 2019 scenario with no PrEP in place would yield 17,424,891 QALYs and a cost of 2018 €17,345,310,254. The present scenario of daily TDF/FTC yields 18,615,325 QALYs, an increase of 1,190,434 QALYs at a cost of 2018 €15,354,878,534 (decrease of -2018 €1,990,431,719), generating an ICER of -2018 €1672 per QALY gained. The introduction of daily TAF/FTC in the present scenario would yield an increase in 449,392 QALYs at an additional cost of 2018 €13,634,260,217. The ICER would thus be 2018 €30,339 per QALY gained. Introducing CAB in the present scenario would yield an increase of 573,007 QALYs at an additional cost of 2018 €16,754,471,790 (average cost-effectiveness ratio=29,239). Compared to TAF, the increase in QALYs would be 123,614 at an additional cost of 2018 €5,707,367,590, yielding an ICER of 2018 €46,170/QALY gained. A one-way sensitivity analysis and a probabilistic sensitivity analysis was carried out. CONCLUSION: The present Spanish policy of PrEP is a cost-saving strategy. TAF/FTC and CAB are not cost-effective at current market prices.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsEmtricitabineTenofovirPre-Exposure ProphylaxisAdenineHIV-1Anti-HIV AgentsPyridonesHumansMaleCost-Benefit AnalysisSpainHomosexuality, MaleQuality-Adjusted Life YearsAlanineAdultDrug Therapy, CombinationSexual and Gender MinoritiesMarkov ChainsDiketopiperazines

Stichwörter der Autor:innen

CabotegravirCost-effectivenessCoste-efectividadHIVHomosexual and gender minoritiesMinorías homosexuales y de géneroPre-exposure prophylaxisProfilaxis preexposiciónTenofovir alafenamidaTenofovir alafenamideVIH

Substanzen

EmtricitabineTenofovirAdenineAnti-HIV AgentscabotegravirPyridonestenofovir alafenamideAlanineemtricitabine tenofovir alafenamideDiketopiperazines

Autor:innen und Institutionen

  • Internal Medicine & Infectious Diseases Department, Elda General University Hospital-FISABIO, Elda, Spain; Clinical Medicine Department, Universidad Miguel Hernández, Elche, Spain. Electronic address: pwikman@umh.es.
  • Faculty of Medicine, University of British Columbia, Vancouver, Canada; Centre of Biomedical Research for Infectious Diseases (CIBERINFEC), Madrid, Spain.
  • Spanish Interdisciplinary AIDS Society (SEISIDA), Madrid, Spain; Centre of Biomedical Research for Infectious Diseases (CIBERINFEC), Madrid, Spain.
  • Centre of Biomedical Research for Infectious Diseases (CIBERINFEC), Madrid, Spain; HIV Unit, Institute for Healthcare Research Hospital 12 de Octubre (imas12), Universidad Complutense de Madrid, Madrid, Spain.
  • Clinical Medicine Department, Universidad Miguel Hernández, Elche, Spain; Centre of Biomedical Research for Infectious Diseases (CIBERINFEC), Madrid, Spain; Infectious Diseases-Internal Medicine Department, Hospital Veg…

Zitieren

APA

Wikman-Jorgensen, P. E., Ruiz-Algueró, M., Iniesta, C., Pulido, F., & Llenas-García, J. (2025). Cost-effectiveness of cabotegravir versus tenofovir alafenamide plus emtricitabine versus tenofovir disoproxil fumarate plus emtricitabine for pre-exposure prophylaxis to prevent HIV-1 transmission in gay, bisexual and other men that have sex with men. Enfermedades infecciosas y microbiologia clinica (English ed.). https://doi.org/10.1016/j.eimce.2024.12.014

Vancouver

Wikman-Jorgensen PE, Ruiz-Algueró M, Iniesta C, Pulido F, Llenas-García J. Cost-effectiveness of cabotegravir versus tenofovir alafenamide plus emtricitabine versus tenofovir disoproxil fumarate plus emtricitabine for pre-exposure prophylaxis to prevent HIV-1 transmission in gay, bisexual and other men that have sex with men. Enfermedades infecciosas y microbiologia clinica (English ed.). 2025. doi:10.1016/j.eimce.2024.12.014

BibTeX
@article{WikmanJorgensen2025,
  author = {Wikman-Jorgensen, Philip Erick and Ruiz-Algueró, Marta and Iniesta, Carlos and Pulido, Federico and Llenas-García, Jara},
  title = {Cost-effectiveness of cabotegravir versus tenofovir alafenamide plus emtricitabine versus tenofovir disoproxil fumarate plus emtricitabine for pre-exposure prophylaxis to prevent HIV-1 transmission in gay, bisexual and other men that have sex with men},
  journal = {Enfermedades infecciosas y microbiologia clinica (English ed.)},
  year = {2025},
  doi = {10.1016/j.eimce.2024.12.014}
}
Kostenlos starten →